6 results about "Plasma dna" patented technology

The invention discloses a lung nodule diagnosis method based on plasma DNA methylation characteristics and application, and the method comprises the following steps: S1, collecting peripheral blood of a subject in a special cfDNA preservation tube, carrying out centrifugal separation to obtain plasma, extracting cfDNA by adopting an optimized paramagnetic particle method or column extraction method, carrying out quality control on the cfDNA, then carrying out thorough hydrosulphite conversion treatment on the cfDNA, and carrying out purification treatment on the cfDNA to obtain the plasma; unmethylated cytosine is converted into uracil, and methylated cytosine is kept unchanged. The invention is derived from the selection of an early and stable epigenetic marker of DNA methylation, and replaces traditional dependent clinical parameters or mutation signals appearing at a late stage. According to the method, the problem of insufficient discrimination capability (AUClt; 0.60) caused by limited input information of an existing clinical prediction model (such as a MayoClinic model) is directly solved.

Methods and kits are provided for determining the efficiency of separating plasma from whole blood using PCR amplification or high-throughput sequencing data of genomic loci present at different concentrations in plasma DNA and whole blood DNA.

Methods are provided to improve the positive predictive value for cancer detection using cell-free nucleic acid samples. Various embodiments are directed to applications (e.g., diagnostic applications) of the analysis of the fragmentation patterns and size of cell-free DNA, e.g., plasma DNA and serum DNA, including nucleic acids from pathogens, including viruses. Embodiments of one application can determine if a subject has a particular condition. For example, a method of present disclosure can determine if a subject has cancer or a tumor, or other pathology. Embodiments of another application can be used to assess the stage of a condition, or the progression of a condition over time. For example, a method of the present disclosure may be used to determine a stage of cancer in a subject, or the progression of cancer in a subject over time (e.g., using samples obtained from a subject at different times).

The technology provided herein relates to amplification-based detection of bisulfite treated DNA, and in particular, but not exclusively, to methods and compositions for multiplex amplification of low levels of sample DNA prior to further characterization of the sample DNA. The technology also provides methods for isolating DNA from a blood or blood product sample, such as a plasma sample.

Pancreatic adenocarcinoma has the worst overall mortality of any solid tumor, with only 7% of patients surviving after 5 years. To evaluate the clinical implications of genomic alterations in this low cellularity tumor type, we deeply sequenced the genomes of 101 enriched pancreatic adenocarcinomas from patients who underwent potentially curative resections and used non-invasive approaches to examine tumor specific mutations in the circulation of these patients. These analyses revealed somatic mutations in chromatin regulating genes including MLL and ARID1A in 20% of patients that were associated with improved survival. Liquid biopsy analyses of cell free plasma DNA revealed that 43% of patients with localized disease had detectable circulating tumor DNA (ctDNA) in their blood at the time of diagnosis. Detection of ctDNA after resection predicted clinical relapse and poor outcome, and disease recurrence by ctDNA was detected 6.5 months earlier than with standard CT imaging.

The invention discloses a composition for detecting methylation of a human plasma SOX15 gene and an EME1 gene for lung cancer, which can be used for realizing early screening and early diagnosis of the lung cancer through detection of plasma DNA (Deoxyribonucleic Acid). Meanwhile, the invention further provides a kit for methylation of the SOX15 gene and the EME1 gene, the sensitivity of detection of lung cancer patients reaches 83.49%, and the specificity is 92.10%.